AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21242784 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional treatment)
Number of subjects: 28
Study 18324601 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined programme (intensive psychosocial relapse-prevention + anxiety treatment with cognitive behavioural therapy and optional SSRI)
Number of subjects: 96
Study 18324601 — intervention group
Group type: COMPARATOR
Intervention: Intensive psychosocial relapse-prevention programme only
Number of subjects: 96
Study 16606474 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematocrit of 20% during normothermic CPB
Number of subjects: 54
Study 16606474 — intervention group
Group type: COMPARATOR
Intervention: Hematocrit of 25% during normothermic CPB
Number of subjects: 54
Study 12957248 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term androgen deprivation (STAD) for 3 months
Number of subjects: 296
Study 12957248 — intervention group
Group type: COMPARATOR
Intervention: RT dose <75 Gy + STAD (Group A)
Number of subjects: 296
Study 12957248 — intervention group
Group type: COMPARATOR
Intervention: RT dose >=75 Gy alone (Group B)
Number of subjects: 296
Study 10897156 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of lamotrigine (100 mg)
Number of subjects: 12
Study 10897156 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of lamotrigine (100 mg)
Number of subjects: 12
Study 8847295 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO (500 IU.kg‐1.wk‐1 for 6 wk)
Number of subjects: 14
Study 8847295 — intervention group
Group type: COMPARATOR
Intervention: rhEPO (100 IU/kg)
Number of subjects: 14
Study 8847295 — intervention group
Group type: COMPARATOR
Intervention: Adults (control group)
Number of subjects: 14
Study 1570385 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% nitrous oxide
Number of subjects: 0
Study 1570385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1570385 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide administered during acquisition
Number of subjects: 0
Study 1570385 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 0
Study 3880523 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg orally)
Number of subjects: 6
Study 3880523 — intervention group
Group type: COMPARATOR
Intervention: Atropine (0.04 mg/kg i.v.)
Number of subjects: 6
Study 3880523 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium (10 mg i.v.)
Number of subjects: 6
Study 3880523 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg orally) and Edrophonium (10 mg i.v.)
Number of subjects: 6
Study 30402987 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study 30402987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29976193 — intervention group
Group type: EXPERIMENTAL
Intervention: Social and Therapeutic Horticulture (STH) intervention with 6 monthly sessions led by horticulturists and a psychotherapist
Number of subjects: 36
Study 29976193 — intervention group
Group type: COMPARATOR
Intervention: Wellbeing Check Cards
Number of subjects: 36
Study 26965019 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged ≤45 years
Number of subjects: 795
Study 26965019 — intervention group
Group type: COMPARATOR
Intervention: Patients aged >45 years
Number of subjects: 795
Study 26965019 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a predictor of MACE
Number of subjects: 795
Study 26965019 — intervention group
Group type: EXPERIMENTAL
Intervention: Both age groups
Number of subjects: 795
Study 24742508 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 °C normal saline nasal irrigation
Number of subjects: 60
Study 24742508 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 °C normal saline nasal irrigation
Number of subjects: 60
Study 24742508 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 °C normal saline nasal irrigation
Number of subjects: 60
Study 24742508 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 healthy individuals)
Number of subjects: 60
Study 24349486 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured insoles
Number of subjects: 40
Study 24349486 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth insoles
Number of subjects: 40
Study 24349486 — intervention group
Group type: COMPARATOR
Intervention: Control (no insoles)
Number of subjects: 40
Study 20598993 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg pretreatment before PCI
Number of subjects: 2014
Study 18240191 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive exercise therapy (IET)
Number of subjects: 85
Study 18240191 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 85
Study 16953999 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention to improve the management of obesity in primary care
Number of subjects: 23
Study 16953999 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention
Number of subjects: 23
Study 14735555 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 0
Study 14735555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14735555 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa and Placebo
Number of subjects: 0
Study 11889647 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical self-regulation training (PSR)
Number of subjects: 44
Study 11889647 — intervention group
Group type: COMPARATOR
Intervention: Standard dental care (SDC)
Number of subjects: 44
Study 11245027 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with CP (cisplatin + cyclophosphamide) or CAP (CP + adriamycin) regimen
Number of subjects: 18
Study 11245027 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Number of subjects: 18
Study 11245027 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (CP, CAP, or CEP, E = VP16)
Number of subjects: 18
Study 7841276 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Compression-Decompression (ACD) using a hand-held suction device (CardioPump, Ambu Int.) with compression (30-50 kp) and decompression (10-15 kp) at a frequency of 80/min.
Number of subjects: 56
Study 7841276 — intervention group
Group type: COMPARATOR
Intervention: Standard chest compression according to AHA recommendations.
Number of subjects: 56
Study 3277481 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral atropine 0.04 mg/kg
Number of subjects: 72
Study 3277481 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral atropine 0.02 mg/kg
Number of subjects: 72
Study 3277481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 31076307 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined short‐axis‐and‐long‐axis approach (n = 40)
Number of subjects: 120
Study 31076307 — intervention group
Group type: COMPARATOR
Intervention: Short‐axis out‐of‐plane approach (SA‐OOP) (n = 40)
Number of subjects: 120
Study 31076307 — intervention group
Group type: COMPARATOR
Intervention: Long‐axis in‐plane approach (LA‐IP) (n = 40)
Number of subjects: 120
Study 31076307 — intervention group
Group type: COMPARATOR
Intervention: Combined short‐axis‐and‐long‐axis approach vs SA‐OOP
Number of subjects: 120
Study 31076307 — intervention group
Group type: COMPARATOR
Intervention: Combined short‐axis‐and‐long‐axis approach vs LA‐IP
Number of subjects: 120
Study 28521880 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2-0.3mg HC/kg body weight/day
Number of subjects: 46
Study 28521880 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4-0.6mg HC/kg body weight/day
Number of subjects: 46
Study 28521880 — intervention group
Group type: COMPARATOR
Intervention: Both doses
Number of subjects: 46
Study 28521880 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose
Number of subjects: 46
Study 26041653 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief behavioural intervention to promote regular self-weighing, including daily weighing encouragement and support materials such as a weight record card
Number of subjects: 560
Study 26041653 — intervention group
Group type: COMPARATOR
Intervention: Weight maintenance leaflet, a diagram representing healthy diet composition, and a list of websites for weight control
Number of subjects: 560
Study 23216882 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus chlorhexidine digluconate and dihydrochloride
Number of subjects: 10
Study 23216882 — intervention group
Group type: COMPARATOR
Intervention: SRP plus chlorhexidine gluconate
Number of subjects: 10
Study 21885349 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizures of mesial temporal lobe origin
Number of subjects: 14
Study 21885349 — intervention group
Group type: COMPARATOR
Intervention: Interictal periods
Number of subjects: 14
Study 19358503 — intervention group
Group type: EXPERIMENTAL
Intervention: Opposing needling
Number of subjects: 60
Study 19358503 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 60
Study 16428568 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgluteal approach (n = 28)
Number of subjects: 56
Study 16428568 — intervention group
Group type: COMPARATOR
Intervention: Popliteal approach (n = 28)
Number of subjects: 56
Study 15571424 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus ribavirin
Number of subjects: 60
Study 15571424 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha-2b plus ribavirin
Number of subjects: 60
Study 11312429 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied twice daily for 6 weeks
Number of subjects: 99
Study 11312429 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied once daily for 6 weeks
Number of subjects: 99
Study 11312429 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied twice daily 3 times/week for 6 weeks
Number of subjects: 99
Study 11312429 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied once daily 3 times/week for 6 weeks
Number of subjects: 99
Study 9209663 — intervention group
Group type: EXPERIMENTAL
Intervention: High GST activity (median: 298 units, range: 50-691)
Number of subjects: 0
Study 9209663 — intervention group
Group type: EXPERIMENTAL
Intervention: High GST activity (> 250 units)
Number of subjects: 0
Study 9209663 — intervention group
Group type: EXPERIMENTAL
Intervention: High GST activity
Number of subjects: 0
Study 9209663 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III-IV ovarian cancer patients with high GST activity
Number of subjects: 0
Study 7956718 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (5 mg/kg) in oral solution
Number of subjects: 6
Study 30804169 — intervention group
Group type: EXPERIMENTAL
Intervention: Faculty feedback
Number of subjects: 126
Study 30804169 — intervention group
Group type: COMPARATOR
Intervention: Peer feedback
Number of subjects: 126
Study 29246455 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-point cane
Number of subjects: 50
Study 29246455 — intervention group
Group type: COMPARATOR
Intervention: Self-stretching exercises
Number of subjects: 50
Study 26683593 — intervention group
Group type: EXPERIMENTAL
Intervention: rt‐PA + Gs
Number of subjects: 2
Study 26683593 — intervention group
Group type: COMPARATOR
Intervention: rt‐PA + placebo (Pc)
Number of subjects: 2
Study 25173483 — intervention group
Group type: EXPERIMENTAL
Intervention: M-001 (500 mcg, non-adjuvanted or adjuvanted)
Number of subjects: 120
Study 25173483 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study 22850914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (IT) with weekly visits for medication adjustments and educational plan for six weeks
Number of subjects: 53
Study 22850914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (IT)
Number of subjects: 53
Study 22850914 — intervention group
Group type: COMPARATOR
Intervention: Both groups (IT and CT)
Number of subjects: 53
Study 20348452 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate only (Group A)
Number of subjects: 150
Study 20348452 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxerutin only (Group B)
Number of subjects: 150
Study 20348452 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate and oxerutin (Group C)
Number of subjects: 150
Study 18408560 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (short-acting beta2-agonist)
Number of subjects: 607
Study 18408560 — intervention group
Group type: EXPERIMENTAL
Intervention: CRHR2 genetic variants
Number of subjects: 607
Study 15759530 — intervention group
Group type: EXPERIMENTAL
Intervention: Bobath treatment
Number of subjects: 44
Study 12426503 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination of secondary caries in crowned teeth
Number of subjects: 100
Study 12426503 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic evaluation of secondary caries in crowned teeth
Number of subjects: 100
Study 12426503 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination of nonrestored teeth
Number of subjects: 100
Study 10494484 — intervention group
Group type: EXPERIMENTAL
Intervention: CVR with 15 micrograms ethinyl estradiol
Number of subjects: 61
Study 10494484 — intervention group
Group type: EXPERIMENTAL
Intervention: CVR with 20 micrograms ethinyl estradiol
Number of subjects: 61
Study 10494484 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CVR
Number of subjects: 61
Study 7794542 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured questionnaires
Number of subjects: 520
Study 7794542 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth interviews
Number of subjects: 520
Study 7794542 — intervention group
Group type: COMPARATOR
Intervention: GPA questionnaire
Number of subjects: 520
Study 1791612 — intervention group
Group type: EXPERIMENTAL
Intervention: nisoldipine 5 mg twice daily
Number of subjects: 28
Study 1791612 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine 10 mg twice daily
Number of subjects: 28
Study 1791612 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study 6794462 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol
Number of subjects: 35
Study 6794462 — intervention group
Group type: COMPARATOR
Intervention: placebo (sterile water)
Number of subjects: 35
Study 6794462 — intervention group
Group type: EXPERIMENTAL
Intervention: disodium cromoglycate
Number of subjects: 35
Study 31452920 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioural treatment
Number of subjects: 36
Study 31452920 — intervention group
Group type: EXPERIMENTAL
Intervention: ENHANCED (technology-supported treatment with digital scale and Fitbit Zip)
Number of subjects: 36
Study 31452920 — intervention group
Group type: EXPERIMENTAL
Intervention: ENHANCED
Number of subjects: 36
Study 31452920 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioural treatment and ENHANCED
Number of subjects: 36
Study 31154955 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to health information (electronic and print media)
Number of subjects: 4104
Study 31154955 — intervention group
Group type: EXPERIMENTAL
Intervention: Wealth improvements in key sectors (education, employment, social protection, housing, and infrastructure)
Number of subjects: 4104
Study 31154955 — intervention group
Group type: EXPERIMENTAL
Intervention: Utilization of mosquito nets
Number of subjects: 4104
Study 27104325 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapula stabilizing t-shirt
Number of subjects: 32
Study 27104325 — intervention group
Group type: COMPARATOR
Intervention: Control group (no t-shirt)
Number of subjects: 32
Study 24814607 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TOP)
Number of subjects: 171
Study 24814607 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent monetary voucher incentives (CM)
Number of subjects: 171
Study 24814607 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TOP) with Contingent monetary voucher incentives (CM)
Number of subjects: 171
Study 24814607 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 171
Study 22490950 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Loteprednol Etabonate ophthalmic suspension
Number of subjects: 34
Study 22490950 — intervention group
Group type: COMPARATOR
Intervention: 1% Cyclosporine A eye drops
Number of subjects: 34
Study 19795444 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR) on 1 antral biopsy
Number of subjects: 1948
Study 19795444 — intervention group
Group type: COMPARATOR
Intervention: Histopathology (hematoxylin‐eosin and Giemsa staining) on 5 biopsies (antrum and corpus)
Number of subjects: 1948
Study 19795444 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR) on 1 biopsy
Number of subjects: 1948
Study 19795444 — intervention group
Group type: COMPARATOR
Intervention: Histopathology on 5 biopsies
Number of subjects: 1948
Study 19795444 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR)
Number of subjects: 1948
Study 17540851 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-slice CT angiography
Number of subjects: 243
Study 17540851 — intervention group
Group type: EXPERIMENTAL
Intervention: 64-slice CT angiography
Number of subjects: 243
Study 16158308 — intervention group
Group type: EXPERIMENTAL
Intervention: TGDc‐01 tonometry
Number of subjects: 68
Study 16158308 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometry
Number of subjects: 68
Study 12021221 — intervention group
Group type: EXPERIMENTAL
Intervention: tirofiban/heparin
Number of subjects: 0
Study 12021221 — intervention group
Group type: COMPARATOR
Intervention: heparin alone
Number of subjects: 0
Study 12021221 — intervention group
Group type: EXPERIMENTAL
Intervention: tirofiban
Number of subjects: 0
Study 10208508 — intervention group
Group type: EXPERIMENTAL
Intervention: Model topical agent
Number of subjects: 14
Study 10208508 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 14
Study 7762709 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide education in Pawtucket
Number of subjects: 0
Study 7762709 — intervention group
Group type: COMPARATOR
Intervention: Comparison community
Number of subjects: 0
Study 1972611 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (0.1 mg/kg i.v. bolus over 30 s)
Number of subjects: 20
Study 1972611 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (loading dose 500 micrograms/kg over 1 min followed by 100 micrograms/kg per min continuous infusion)
Number of subjects: 20
Study 1972611 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 20
Study 418585 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral thyrotropin releasing hormone (TRH) 40 mg
Number of subjects: 16
Study 418585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31765428 — intervention group
Group type: COMPARATOR
Intervention: Four-component combination pill (polypill)
Number of subjects: 0
Study 29512470 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 0
Study 29512470 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 0
Study 29512470 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib
Number of subjects: 0
Study 29512470 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib
Number of subjects: 0
Study 29512470 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib
Number of subjects: 0
Study 27640727 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypodermoclysis administered by caregivers after a 45-minute training session
Number of subjects: 21
Study 24794289 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious games (SG) as an adjuvant to conventional treatment
Number of subjects: 352
Study 24794289 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment for CP
Number of subjects: 352
Study 22421927 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg BID
Number of subjects: 604
Study 22421927 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg QD
Number of subjects: 604
Study 22421927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 604
Study 20380655 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg/day
Number of subjects: 264
Study 20380655 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.9 mg/day
Number of subjects: 264
Study 20380655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 18025845 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic bupivacaine (0.5% 20 ml) injection (group I)
Number of subjects: 40
Study 18025845 — intervention group
Group type: EXPERIMENTAL
Intervention: Total tramadol consumption in group I
Number of subjects: 40
Study 18025845 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia demands in group I
Number of subjects: 40
Study 18025845 — intervention group
Group type: COMPARATOR
Intervention: Control (saline NaCl 0.9% 20 ml injection, group II)
Number of subjects: 40
Study 16192551 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver (blew into sphygmomanometer tubing and raised the mercury column up to 30 mm Hg for 20 s)
Number of subjects: 75
Study 16192551 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 75
Study 16192551 — intervention group
Group type: COMPARATOR
Intervention: Ball pressing (pressed a rubber ball)
Number of subjects: 75
Study 12831918 — intervention group
Group type: EXPERIMENTAL
Intervention: Toupet fundoplication (TF)
Number of subjects: 33
Study 12831918 — intervention group
Group type: COMPARATOR
Intervention: Nissen‐Rossetti fundoplication (NF)
Number of subjects: 33
Study 10671817 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM group (n=33)
Number of subjects: 41
Study 10671817 — intervention group
Group type: COMPARATOR
Intervention: Normal pregnant women (n=62)
Number of subjects: 41
Study 8848917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low flow rate anesthesia with heat moisture exchanger
Number of subjects: 40
Study 8848917 — intervention group
Group type: COMPARATOR
Intervention: High fresh gas flow rates with heat moisture exchanger
Number of subjects: 40
Study 1535653 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean HBV vaccine
Number of subjects: 922
Study 1535653 — intervention group
Group type: COMPARATOR
Intervention: U.S. HBV vaccine
Number of subjects: 922